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The lecture will review experimental and clinical evidence for
an involvement of the endothelin system in promoting glomerular
dysfunction and damage. We will propose a network of pathophysio-
logical interactions involving paracrine effects of ET-1 in the distinct
glomerular cells. At last, the lecture will tease out speciﬁc pathophys-
iological contexts where clinical development are expected to bring
fruits and would meet therapeutic needs.
We will focus on experimental evidence for a regulatory role of
E T-1 in podocyte function and hypothesize non-exclusive patho-
physiological involvement of the ET-1 system in different glomerular
diseases with podocyte injury. First, ET-1 produced by injured glo-
merular or preglomerular endothelium could be freely ﬁltered through
the ﬁltration barrier and act on podocyte ETRs. This is expected to occur
in severe hypertension, hemolytic uremic syndrome (HUS) and throm-
botic microangiopathy (TMA), sickle cell disease, diabetic nephropathy
(DN), connective tissue diseases and vasculitis. We will brieﬂy review
evidences for increased ET-1 activity in the vasculature in IgA nephrop-
athy (IgAN) where vascular lesions are frequent and of prognostic
value. Second, ET-1 may be produced de novo by mesangial cells.
We will review the current evidence for ET-1 production by mesangial
cells, in particular in DN and IgAN. Third, scarce evidence suggest
that podocytes and glomerular parietal epithelial cells produce ET-1
that affects podocyte phenotype in a paracrine and autocrine fashion in
vitro. In this regard we will examine the current evidences in focal and
segmental glomerulosclerosis (FSGS) and crescentic glomerulonephri-
tis. This review and further studies may assist clinicians in optimally
designing clinical trials for patients at increased risk for CKD.
doi:10.1016/j.lfs.2013.12.202
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Circulating levels of the endothelium-derived peptide endothelin-1
(ET-1) are elevated in human obesity, and ET-1 mediated vascular
tone is increased. The renal artery is important in controlling intrarenal
blood ﬂow and is highly sensitive to ET-1. Whether or not ET-1 affects
renal artery tone in obesity is unknown. To investigate the role of
endogenous ET-1, a mouse model with tie-1 promoter-driven endo-
thelium-restricted heterozygous overexpression of preproendothelin-1
was used (TET+/−). Obesity was induced in TET+/− and WT
littermates by feeding a high fat diet for seven months; lean controls
were kept on standard chow. The main renal arteries were studied in
wire myographs testing contractions (in the presence of l-NAME) to
ET-1, serotonin (5-HT), and U46619, targeting ETA, 5-HT2, and TP
receptors, respectively. Contractions to ET-1 were comparable be-
tween groups (PD2 8.29 ± 0.05, n = 6–8); 5-HT-induced responses
were facilitated at lower concentrations in obese mice leading to a shift
in PD2 (lean 7.08 ± 0.02 vs. obese 7.23 ± 0.07, n = 5–8, P b 0.01).
Responses to U46619 were signiﬁcantly shifted to the left in renal
arteries of obese animals (PD2 8.57 ± 0.06 vs. lean 8.21 ± 0.05, n = 5–
8, P b 0.001), and the area under the curve was signiﬁcantly different
between lean and obese TET+/− mice (AUC 418 ± 23 vs. lean 319 ±
25, n = 5, P b 0.05). Thus, TET+/− had no effect on responses in lean
animals. By contrast, in obesity heterozygous overexpression of ppET-1
enhanced TXA2-mediated, but not 5-HT or ET-1 induced contractions of
the renal artery.
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The effect of proteinuria-mediated endothelin-1 downregulation
of PKCα signalling in proximal tubular cells and its successful
treatment is measurable using microRNA15a as biomarker in
vitro and in vivo
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In proteinuric diseases, stimulation of proximal tubule cells (RPTECs)
by protein and endothelin-1 result in the activation of different
signal pathways, ultimately causing renal insufﬁciency. Therapeutic
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